A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Sjogren's Disease

Recruiting

Phase 1

CLN-978A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Sjogren's Disease

Sponsor:

Cullinan Therapeutics Inc.

Code:

NCT07041099

Conditions

Sjögren

Sjogren Disease

Sjogren's Syndrome

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

CLN-978

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-01-15. This information was provided to ClinicalTrials.gov by Cullinan Therapeutics Inc. on 2025-11-19.